Abstract:This study tested the hypothesis that GLP‐1 based therapies improve cardiac contractile function at rest and in response to beta‐adrenergic stimulation in an obese swine model of ischemic heart disease. Ossabaw swine were fed a high calorie, obesogenic diet for 6 months. Following this period, swine were subjected to a gradually developing coronary occlusion by placement of an ameroid occluder on the left anterior descending (LAD) coronary artery. Animals then received daily subcutaneous injections of saline or the stable GLP‐1 analogue liraglutide (0.005–0.015mg/kg/day) for 30 days. Following this treatment, animals were anesthetized and an open chest procedure was performed to assess cardiac performance in response to a sympathomimetic challenge (dobutamine 0.3–10 μg/kg/min) using a left ventricular pressure/volume admittance catheter. Liraglutide administration did not influence the magnitude of myocardial infarction in response to LAD occlusion (saline 16 ± 2% vs liraglutide 14 ± 4%; P = 0.8). Baseline cardiac output and ejection fraction were not different between treatment groups at rest or in response to dobutamine. Thirty days of treatment with liraglutide did not modify the effects of dobutamine to increase pulse pressure, heart rate, dP/dtmax, or contractility index. Indices of diastolic relaxation during dobutamine stimulation were augmented in liraglutide treated animals (dP/dt min P < 0.001, Tau 1⁄2 P <0.001, Tau 1/e P < 0.001). Dobutamine reduced left ventricular end diastolic volume, end systolic volume, and stroke volume similarly in saline and liraglutide treated animals. However, the slope of the end systolic pressure volume relationship (ESPVR; load‐independent contractility) was significantly increased by dobutamine following liraglutide (4.2 ± 1.1 vs 21.8 ± 8.4 mmHg/ml; P <0.001) but not saline (8.7 ± 5.9 vs 14.8 ± 3.5 mmHg/ml; P = 0.63). Dobutamine increased the volume axis intercept (Vo) of ESPVR in both groups, but this effect was ~50% smaller in animals treated with liraglutide at the lower dobutamine infusion rates (0.3 and 1 μg/kg/min; P < 0.05). While cardiac efficiency (stroke work/pressure volume area) was similar between treatment groups at baseline (70 ± 7% vs 69 ± 3; P = 0.92), liraglutide significantly enhanced cardiac efficiency under the highest dobutamine infusion rate (10 μg/kg/min; P = 0.017). Taken together, these data suggest that GLP‐1 agonism augments diastolic relaxation, contractility, and cardiac efficiency under sympathetic stimulation in the setting of obesity and regional myocardial infarction. Support or Funding Information This study was supported by R01HL11760 (J. Tune and K. Mather, PI). Dr. Goodwill was supported by American Heart Association 13POST1681001813 (A. Goodwill, PI). Ms. Noblet and Mr. Sassoon were supported by TL1 TR000162 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award.

Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet

Liraglutide Improves Renal Endothelial Function in Obese Zucker Rats on a High-Salt Diet

Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin‐induced diabetic rats

Glp-1 Analog, Liraglutide, Ameliorates Hepatic Steatosis and Cardiac Hypertrophy in C57BL/6J Mice Fed a Western Diet.

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation

[The Renal Protective Effect and Mechanism of Liraglutide in Diabetic Mice Induced by High-Fat Diet].

The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling

482-P: The GLP-1 Receptor Agonist Liraglutide Improves Glomerular Filtration Rate, Renal Inflammation, and Fibrosis in the Type 2 Diabetic SDT Fatty Rat

The Long Acting GLP‐1 Receptor Agonist, Liraglutide, Augments Myocardial Contractile Responses and Cardiac Efficiency Under Sympathetic Stimulation in Obesity and Myocardial Infarction

Liraglutide Ameliorates Palmitate-Induced Endothelial Dysfunction Through Activating AMPK and Reversing Leptin Resistance.

Unlocking the miRNA-34a-5p/TGF-β and HMGB1/PI3K/Akt/mTOR crosstalk participate in the enhanced cardiac protection of liraglutide against isoproterenol-induced acute myocardial injury rat model

Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuated Diabetic Retinal Edema in Spontaneously Diabetic Torii Fatty Rats

Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control

Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR/p70S6K signaling and promoting autophagy

Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats

Glucagon-Like Peptide-1 Analogue Liraglutide Ameliorates Atherogenesis Via Inhibiting Advanced Glycation End Product-Induced Receptor for Advanced Glycosylation End Product Expression in Apolipoprotein-E Deficient Mice

Liraglutide Alleviates Cardiac Fibrosis Through Inhibiting P4hα-1 Expression in STZ-induced Diabetic Cardiomyopathy

Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells

Liraglutide Reduces Hepatic Glucolipotoxicity‑induced Liver Cell Apoptosis Through NRF2 Signaling in Zucker Diabetic Fatty Rats

Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis